宫内节育器不同铜表面积对月经血量的影响

对健康妇女随机放置TCu380A和TCu220C IUD后的月经血量变化进行观察,放器前TCu380A和TCu220C组平均月经血量(MBL)为45.3±13.4ml和42.6±11.5ml,放器后1、3、6、12周期平均MBL分别为72.4±41.6ml和73.2+38.3ml;77.0±42.9ml和82.9±46.9ml;73.2±31.2ml和74.5±30.5ml及64.5±18.9ml和68.2±14.4ml;放置两种IUD后MBL较放器前明显增多(P<0.001),但两种IUD间比较,放器后各周期平均MBL无显著差别(P>0.05),提示在一定范围内增加铜的表面积对放器后MBL的增加程度并无显著影响。     

MCu110和TCu220C、TCu380A宫内节育器比较的系统评估

目的：评价MCu110功能性宫内节育器的有效性、副反应和可接受性。方法：通过电子和手工检索查阅2000年1月～2008年12月国内外发表的相关文献,并依照循证医学的方法对纳入评估的文献进行筛选、评价和分析。结果：共获得合格文献10篇,均为随机对照临床试验且正式发表。评估结果显示,置器后12月和24月,MCu110的临床综合效果优于TCu220C;脱落率略低于TCu380A,可接受性略优于TCu380A,副反应各项指标二者互有优劣,而带器妊娠率差别未发现有统计学意义。结论：与TCu380A相比,能够证实MCu110有效性、副反应和可接受性的多中心随机对照试验并不多,尤其是长期随访研究;建议由非MCu110研制单位组织开展多中心随机对照试验,观察年限不少于5年。     

TCu380A、TCu220C和MLCu375宫内节育器系统评估

目的 :评价TCu380A、TCu2 2 0C、MLCu375三种宫内节育器的有效性、副反应和可接受性。方法 :见中国计划生育学杂志“我国常用口服避孕药和宫内节育器系统评估的方法概述”(2 0 0 5年 1期 17页 )。结果 :TCu380AIUD妊娠率及脱落率均低于MLCu375IUD ,副作用发生率高于MLCu375IUD ,续用率等同或高于MLCu375IUD ,临床综合效能与MLCu375IUD相近 ;TCu380AIUD妊娠率低于TCu2 2 0CIUD ,脱落率及安全性与TCu2 2 0CIUD相似 ,放置满 5年后续用率高于TCu2 2 0CIUD ;MLCu375IUD妊娠率略低于TCu2 2 0CIUD ,脱落率低于或等同于TCu2 2 0CIUD ,二者的副反应发生率相似 ,临床综合效能优于TCu2 2 0CIUD。建议 :可以继续使用TCu380AIUD、MLCu375IUD和TCu2 2 0CIUD ,并且加大TCu380AIUD和MLCu375IUD的使用份额。在总体上应优先考虑提供铜表面积≥ 30 0mm2 的宫内节育器     

GyneFix330和TCu220C、TCu380A宫内节育器比较的系统评估

目的:评价GyneFix330与TCu220C、TCu380A宫内节育器(IUD)的有效性、副反应和续用情况。方法:电子和手工检索1990年1月~2009年11月中英文发表的相关文献,按循证医学方法对纳入文献进行分析评价。结果:纳入26篇正式发表的随机对照临床试验文献。与TCu220C IUD相比,GyneFix330IUD的12个月和24个月带器妊娠率和脱落率较低;6个月、12个月和24个月的经期延长、经量增多、腰腹痛和不规则出血发生率较低;12个月因症取出率较低,续用率则较高。GyneFix330和TCu380A IUD12个月、24个月、36个月和9年的带器妊娠率均低于2.50/100妇女。两组6个月、12个月、24个月和36个月的月经量增多、白带增多和不规则出血发生率互有优劣。与TCu380A IUD相比,Gyne-Fix330IUD12个月和24个月的因症取出率接近,续用率略高。结论:GyneFix330IUD临床应用效果优于TCu220C IUD,与TCu380A IUD相差不大,仍需长期大样本临床观察予以确证。     

TCu 380A IUD: a reversible permanent contraceptive method in women over 35 years of age

OBJECTIVE: The objective of the study was to evaluate the performance of the TCu 380A IUD in women who had been using the device for more than 10 years and who were 35 years of age or more on completion of the 10th year of IUD use. METHODS: A total of 228 women who had an IUD inserted between 1987 and 1992 were included in the study. The cutoff date for analysis was January 31, 2004. Clinical performance was evaluated by life-table analysis. The mean age of women at 10 years of use was 38.8+/-0.4 years and mean parity was 2.2+/-0.08 (mean+/-SD). The duration of follow-up beyond 10 years ranged from 1 to 72 months. No pregnancy was observed in 366 woman-years of observation beyond 10 years of use. The main reason for discontinuation was removal of the device because the clients had previously been informed that the IUD was not approved for use beyond 10 years. This reason accounted for a gross cumulative 6 years discontinuation rate of 42.5 per 100 women beyond 10 years. The other main reasons for discontinuation beyond 10 years of use were surgical sterilization, menopause and expulsion with gross cumulative 6-year termination rates of 19.2, 11.0 and 21.2 per 100 women, respectively. The cumulative continuation rate beyond 10 years was 67.0 at the end of the first year of follow-up and 21.2 at the end of the sixth year. CONCLUSION: We found no evidence that the TCu 380A IUD loses its effectiveness after 10 years of use. RESULTS: The concept that women who have insertion of a TCu 380A IUD at the age of 25 years or older could use this IUD as a reversible but permanent method of contraception up to the menopause continues to be supported by the accumulation of evidence, although definitive evidence remains to be obtained.     

MCu IUD放置8年多中心临床比较性研究

目的:观察MCu IUD的临床效果及安全性。方法:国内6个临床中心按统一标准选择1100例要求使用IUD避孕的妇女,随机放置MCu IUD与TCu380A IUD各550例,定期随访观察96个月。结果:放置满96个月时,MCu组与TCu380A组的继续使用率分别为每百妇女年77.09,72.18(P>0.05);带器妊娠率分别为每百妇女年2.50,3.42(P>0.05);脱落率分别为每百妇女年1.07,5.73,差异有极显著性意义(P<0.001);因出血/疼痛取出率分别为每百妇女年5.66,7.77(P>0.05);有副反应主诉分别为每百妇女年4.48,5.54(P<0.05);因计划妊娠取器后足月妊娠分娩两组分别为82.5%,81.08%,总妊娠率均在90%以上。结论:MCu IUD脱落率低、避孕效果和可逆性好,是比较理想的IUD。     

月经间期放置MYCu宫内节育器临床效果的比较性研究

目的:了解第三代爱母宫内节育器(MYCu IUD)在月经间期放置的临床效果、副作用及对生活质量的影响。方法:对要求放置IUD避孕的育龄妇女,在月经间期随机放置MYCu IUD(MYCu组,368例)与TCu 380AIUD(TCu380A组,369例),放置后1、3、6、12个月随访观察,记录使用情况。结果:置器后12个月MYCu组与TCu 380A组随访率分别为99.45%、100.00%;置器12个月累积续用率分别为每百妇女年94.02、91.87(P0.05);带器妊娠率分别为每百妇女年0.56、0.00(P=0.1703);脱落率分别为每百妇女年0.57、1.95(P=0.0947);无因IUD下移而停用者;因症终止率分别为每百妇女年3.01、6.03(P=0.0849)。置器后1、3、6个月副作用发生率MYCu组明显低于TCu380A组(P0.05)。两组对象相关生活质量均得到改善。结论:放置MYCu IUD较TCu 380AIUD疼痛和出血的副作用少,续用率、避孕效果与TCu 380AIUD相当,是一种临床效果好、副作用发生率较低的新型IUD。     

爱母牌MYCu宫内节育器与TCu220C宫内节育器的临床应用对比

目的探讨爱母牌MYCu宫内节育器(intrauterin econtraceptive device,IUD)与TCu220C宫内节育器(TCu220CIUD)的临床应用效果。方法选择来嘉定中心医院要求放置IUD避孕的育龄妇女,随机放置MYCuIUD与TCu220CIUD各150例,放置后1、3、6、12个月定期随访观察。结果放置满12个月时,MYCuIUD组与TCu220CIUD组累计带器妊娠率均为0.67/每百妇女年,累计脱落率分别为0.67/每百妇女年、2.00/每百妇女年;因不良反应取出率为2.01/每百妇女年、4.14/每百妇女年,差异均无统计学意义(P>0.05);续用率分别为96.00/每百妇女年、92.30/每百妇女年;4次随访主诉发生率MYCuIUD组低于TCu220CIUD组,差异有统计学意义(P<0.05),主诉中最常见的不良反应为出血和疼痛。结论 MYCuIUD抗生育效果好,脱落率低,置器后不良反应小,是效果理想的IUD,值得进一步推广应用。     

TCu220C宫内节育器副反应及其影响因素的meta分析

目的:通过mtea分析评价使用TCu220CIUD副反应发生情况及其相关影响因素,为安全使用提供科学依据。方法:利用计算机检索PubMed、EMBASE、CENTRAL等9种数据库和WHO/FDA/IUD生产企业/临床试验注册相关网站,采用Openmeta analyst软件对数据进行分析。结果:共检索到7726篇文献,根据纳入及排除标准,最终纳入涉及TCu220C副反应的文献15篇,均为RCT或准RCT,共计22253例观察对象,其中TCu220C组7558例。mtea分析表明出血、疼痛和感染副反应及总体发生率均随置器时间延长呈现下降趋势。随访12个月时,国外组TCu220C疼痛、感染和总副反应发生率高于国内组。产褥期末放置对象6个月和12个月随访时的出血发生率高于正常月经间期放置对象。结论:建议医务人员在TCu220CIUD放置初期应关注出血的处理,若为产褥期末放置IUD对象还应加强后期随访,以减少TCu220CIUD副反应的发生。     

两种新型含铜IUD对宫颈沙眼衣原体阳性率影响的研究

本文报道了同期放置的TCu380A及GyneFix两种新型含铜宫内节育器在放置1年及2年时与对照组宫颈砂眼衣原体(CT)阳性率的比较。TCu380A组放置1年时阳性率为5.63％,2年时为4.92％;GyneFix组放置1年时阳性率为4.62％,2年时为5.08％,两组含铜IUD放置1年及2年时各组比较差别均无显著意义(P>0.05);对照组CT阳性率为15.18％,与上述各组比较差别均有显著意义(P<0.05)。本文结论认为含铜IUD对宫颈CT感染有抑制作用。     

Arandomized multicentre trial of the Multiload 375 and TCu380A lUDs in parous women: three-year results

Two copper IUDs—the Multiload 375 and TCu380A—are being studied in a randomized multicentre study in parous women involving nineteen centres in nine countries. There have been 1,832 insertions of the Multiload 375 and 1,823 of the TCu380A. After three years of use, the Multiload 375 had a pregnancy rate that was significantly higher than the TCu380A (2.9 ± 0.4 vs. 1.6 ± 0.3 per 100 women). There were no differences at one, two and three years of use in the expulsion rates. It is concluded that the Multiload 375 shows no clinical advantages over the TCu380A and its extra cost should be an important consideration in the choice of the most appropriate IUD.     

The frameless copper IUD (GyneFix) and the TCu380A IUD: results of an 8-year multicenter randomized comparative trial

Background

Clinical performance of the frameless copper IUD (GyneFix), designed to reduce side effects related to the frame of conventional IUDs, and TCu380A was compared.

Study Design

Randomized Multicenter randomized comparative trial. Parous women requesting and eligible to use IUD were admitted in 21 centers in eight countries in 1989-1993 and followed-up for up to 8 years.

Results

Two thousand twenty-seven women were randomized to the frameless IUD and 2036 to TCu380A; 43 insertions of the frameless IUD failed and none for TCu380A. First-year expulsion rate of the frameless IUD was 5.3 (95% CI: 4.4-6.4) per 100 and 2.5 (95% CI: 1.9-3.3) for the TCu380A; second- through eighth-year expulsion rates were not different. First-year pregnancy rates for the frameless IUD and TCu380A were 1.3 (95% CI: 0.9-2.0) and 0.5 (95% CI: 0.3-0.9), respectively; second- through eighth-year cumulative pregnancy rates were 1.2 (95% CI: 0.7-1.9) and 2.5 (95% CI: 1.8-3.4), respectively. The 8-year cumulative rates of ectopic pregnancy and IUD removal for pain were lower for the frameless IUD than for TCu380A. Removals for other reasons were not different.

Conclusions

The frameless IUD had more insertion failures, expulsions and pregnancies in the first year than TCu380A, but fewer pregnancies from the second through the eighth year, and by 8 years had fewer ectopic pregnancies and removals for pain.     

Use of the Mirena™ LNG-IUS and Paragard™ CuT380A intrauterine devices in nulliparous women: Release date 15 December 2009 SFP Guideline 20092

Two intrauterine devices (IUDs) are available in the United States, the levonorgestrel-bearing intrauterine system (Mirena™) and the copper-bearing T380A (Paragard™). These devices have very low typical-use failure rates but are used by only a minority of women. In particular, there is concern about their use in nulliparous women. We review the available data to address common concerns about using IUDs in this population and show that nulliparous women desiring effective contraception should be considered candidates for IUDs.